Hypergonadotropic Hypogonadism: Management of Infertility
Küçük Resim Yok
Tarih
2021
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Bentham Science Publ Ltd
Erişim Hakkı
info:eu-repo/semantics/closedAccess
Özet
Background: Medical treatments are used either alone or in combination with assisted reproductive techniques for the treatment of infertile patients with hypergonadotropic hypogonadism. A wide range of treatment options such as gonadotropins, aromatase inhibitors (AIs), selective estrogen receptor modulators (SERMs) and their combination are available as options. Objective: The aim of this review was to evaluate treatment options for infertile men with hypergonadotropic hypogonadism. Methods: A literature search of MEDLINE (1980-2019) was conducted using the terms 'hypogonadism', 'male infertility', 'gonadotropins', 'SERMs' and 'AIs'. Pathologies leading to hypergonadotropic hypogonadism and treatment modalities such as gonadotropins, SERMs, AIs and surgical treatment were discussed. Results: FSH increases spontaneous pregnancy rates but the level of evidence was proven to be low for live birth rates. AIs are valid treatment options for patients with low T/E2 ratio as they significantly increase sperm concentrations. SERMs are recommended for infertile males with a sperm concentration between 10-20 million. Varicocele was reported to increase testosterone levels of hypogonadic infertile males. Conclusion: Medical treatment modalities such as gonadotropins, SERMs, AIs and a combination of these therapies has been showed to have some effect in improvement of fertility but is not mainstream of the treatment.
Açıklama
Anahtar Kelimeler
Hypergonadotropic Hypogonadism, Male Infertility, Empirical Medical Treatment, Gonadotropins, Aromatase Inhibitors, Selective Estrogen Receptor Modulators, Testicular Sperm Extraction, Follicle-Stimulating-Hormone, Human Chorionic-Gonadotropin, Idiopathic Male-Infertility, Klinefelter Syndrome, Nonobstructive Azoospermia, Clomiphene Citrate, Varicocele Repair, Compensated Hypogonadism, Aromatase Inhibitors
Kaynak
Current Pharmaceutical Design
WoS Q Değeri
Q3
Scopus Q Değeri
Q2
Cilt
27
Sayı
24
